Presentation ESC 2022 Efficacy and Safety of the Oral Factor XIa Inhibitor, Asundexian, Added to Dual Antiplatelet Therapy After an Acute Myocardial Infarction Presenter: John H. Alexander August 28, 2022
News Conference News ESC 2022 Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke Todd Neale August 28, 2022
News Conference News EAS 2022 FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses Michael O'Riordan May 26, 2022
News Daily News Higher Single-Sample hs-cTnT Threshold Can Safely Exclude MI Michael O'Riordan May 13, 2022
News Daily News Acute MI Workup in Emergency Departments Varies by Sex and Race Michael O'Riordan May 11, 2022
News Daily News Good News and Bad for High-Intensity Statin Use in ASCVD Michael O'Riordan May 05, 2022
News Daily News CVD Hospitalizations Spiked in Aftermath of 2020 US Election Michael O'Riordan April 22, 2022
News Daily News Clopidogrel Superior to ‘Divine’ Aspirin Monotherapy in Secondary Prevention Michael O'Riordan March 30, 2022